US FDA Offers Sponsors More Attention For Sharing Complex Innovative Trial Designs
Executive Summary
Pilot program will select two trial designs per quarter, but sponsors want to know how much information they must disclose.
You may also be interested in...
Boosting Complex Innovative Designs In Clinical Trials: What The Pilots Show
Lilly representative suggests having more informal communication with FDA and consistent feedback across divisions. The firm had a positive experience participating in CID pilot with master protocol for chronic pain therapies.
US FDA, Industry Share Early Lessons From Complex Innovative Trial Designs Program
Timelines in the CID program are tight, and sponsors should have a ‘fully baked’ trial design before heading into their first meeting with the agency, industry reps say; agency needs more simulation data from participating sponsors earlier and is working to ensure continuity for firms after the second of two meetings allowed under the program.
Innovative Trial Designs Are 'Life And Death Matter' For Pharma, Amgen Tells US FDA
Amgen exec calls for more informal agency feedback and alignment between review divisions in understanding design methodologies.